Agios Pharmaceuticals (AGIO) shares were up 27% in recent pre-market trade after saying this weekend that data from a study on the AG-221 drug in patients with advanced blood cancers showed “promising” clinical activity.

AGIO is in the upper half of the 52-week range between $15.77 and $49.79.

The purpose of the phase 1 program was to test safety and tolerability but also demonstrated “multiple complete remissions, in patients whose blood cancers carried an IDH2 mutation, even at the lowest tested dose,” according to the lead investigator, Eytan Stein, at the leukemia service at Memorial Sloan-Kettering Cancer Center.

“These findings corroborate the use of precision medicine in genetically defined patient populations and demonstrate the potential of targeting cancer metabolism to develop transformative medicines for patients,” CEO David Schenkein said in a statement.